[논문]중등도-중증 궤양성 대장염 환자에서 infliximab의 치료효과에 대한 메타분석

김종윤; 이숙향; 유기연

중등도-중증 궤양성 대장염 환자에서 infliximab의 치료효과에 대한 메타분석
Meta-analysis of the Efficacy of Infliximab in Patients with Moderate-Severe Ulcerative Colitis 원문보기

한국임상약학회지 = Korean journal of clinical pharmacy, v.22 no.3, 2012년, pp.251 - 259

김종윤 (동덕여자대학교 약학대학) , 이숙향 (아주대학교 약학대학) , 유기연 (동덕여자대학교 약학대학)

Abstract ▼ AI-Helper

Ulcerative colitis (UC) is characterized by a life-long chronic course with remissions and exacerbations. Use of biological therapies may reduce or delay the surgical procedures in patients with UC. The aim of this study was to determine the impact of infliximab (IFX) use on the rate of remission, surgical interventions, and the effect on quality of life in patients with moderate to severe UC. Literature was searched for studies that investigated the efficacy of IFX on the rate of remission, colectomy and quality of life (QoL) between January 1990 and June 2012 at MEDLINE, January 1988 and June 2012 at EMbase and others. Eleven trials were included in the meta-analysis; divided into placebo controlled 8 trials and intravenous corticosteroid controlled group 3 trials. In comparison to placebo control groups, patients who received IFX had an odds ratio (OR) of 3.712 (95% CI: 2.714, 5.079) for the short-term clinical remission, and 3.053 (95% CI: 2.044, 4.559) for the rate of long-term remission. In colectomy rate and quality of life (QoL), odds ratio were 0.566(95% CI: 0.387, 0.827) and 0.658 (0.505, 0.811) respectively. Any adverse reactions including infections, infusion reaction, rash and arthralgia were equivalent in both groups. Compared with intravenous corticosteroid controlled group, patients who received IFX had lower remission rate with short-term odds ratio 0.227 (95% CI: 0.033, 1.556) and long-term odds ratio 1.054 (95% CI: 0.317, 3.502) respectively. However, statistical significance was not showed with both two analyses. The higher adverse drug reaction (ADR) rates were occurred in the corticosteroid controlled groups. 73.3% of patients treated corticosteroid reported Cushing-like syndrome with moon face. In conclusion, IFX does increase remission rate and decrease the rate of colectomy in patients with UC without elevating any adverse reactions significantly. IFX also improves QoL in moderate to severe UC patients. It would not exceed the efficacy of intravenous corticosteroid, whereas intravenous corticosteroid also reported high rate of adverse reactions.

주제어

참고문헌 (52)

Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006; 12: 6102-6108.

상세보기
Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004; 99: 1371-1385.

상세보기
Willert RP, Lawrance IC. Use of infliximab in the prevention and delay of colectomy in severe steroid dependent and refractory ulcerative colitis. World J Gastroenterol. 2008; 14: 2544-2549.

상세보기
Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology. 1985; 89: 1005-1013.

상세보기
Lichtiger S, Present DH, Kornbluth A, et al., Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330: 1841-1851.

상세보기
Laharie D, Bourreille A, Branche J. et al., Cyclosporin versus infliximab in severe acute ulcerative colitis refractory to intravenous steroids: A randomized trial. Gastroenterology. Conference: Digestive Disease Week, DDW 2011 Chicago, IL United States. Conference Publication: (var.pagings). 140 (5 SUPPL. 1) (pp S112), 2011.
Arts J, D'Haens G, Zeegers M, et al., Long-term outcome of treatment with intravenous cyclosporine in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004; 10: 73-78

상세보기
Pham CQ, Efros CB, Berardi RR. Cyclosporine for severe ulcerative colitis. Ann Pharmacother. 2006; 40: 96-101.

상세보기
Van AG, Vermeire S, Rutgeerts P. Treatment of severe steroid refractory ulcerative colitis. World J Gastroenterol. 2008; 14: 5508-5511.

상세보기
Kim SH, Kim KI, Yun HY, et al., Population Pharmacokinetics of Cyclosporine after Hematopoietic Stem Cell Transplantation in Leukemic Patients. Kor J Clin Pharm. 2010; 20: 9-16.
Shibolet O, Regushevskaya E, Brezis M, et al., Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev. 2005; CD004277.
Penna C, Dozois R, Tremaine W, et al., Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut. 1996; 38: 234-239.

상세보기
McIntyre PB, Pemberton JH, Wolff BG, et al., Comparing functional results one year and ten years after ileal pouchanal anastomosis for chronic ulcerative colitis. Dis Colon Rectum. 1994; 37: 303-307.

상세보기
Hahnloser D, Pemberton JH, Wolff BG, et al., The effect of aging on function and quality of life in ileal pouch patients: a single cohort experience of 409 patients with chronic ulcerative colitis. Ann Surg. 2004; 240: 615-621.

상세보기
Ording OK, Juul S, Berndtsson I, et al., Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology. 2002; 122: 15-19.

상세보기
Kim KO, Jang BI Jang. Emerging Drugs in the Treatment of Inflammatory Bowel Disease: Beyond Anti-TNF- ${\alpha}$ . Korean J Gastroenterol. 2011; 58: 235-244.

상세보기
Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 2000; 119: 1148-1157.

상세보기
Hove T, Montfrans C, Peppelenbosch MP, et al., Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002; 50: 206-211.

상세보기
Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004; 126: 1593-1610.

상세보기
Travassos WJ, Cheifetz AS. Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005; 8: 187-196.

상세보기
Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol. 2006; 40: 476-481.

상세보기
Yamamoto-Furusho JK, Uzcanga LF. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids. Dig Surg. 2008; 25: 383-386.

상세보기
Talley NJ, Abreu MT, Achkar JP, et al., An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011; 106: S2-S25.

상세보기
Jadad AR, Carroll D, Jenkinson C, et al., Assessing the quality of reports of randomized clinical trials: is bliniding necessary? Control Clin Trials. 1996; 17: 1-12.

상세보기
Clark HD, Wells GA, Huet C, et al., Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials. 1999; 20: 448-452.

상세보기
Cochran WG. The combination of estimates from different experiments. Biometrics. 1954; 10: 101-129

상세보기
Gustavsson A, Jarnerot G, Hertervig E, et al., Clinical trial: colectomy after rescue therapy in ulcerative colitis 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther. 2010; 32: 984-989.

상세보기
Sandborn WJ, Rutgeerts P, Feagan BG, et al., Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009; 137: 1250-1260.

상세보기
Feagan BG, Reinisch W, Rutgeerts P et al., The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007; 102: 794-802.

상세보기
Gavalas E, Kountouras J, Stergiopoulos C, et al., Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients. Hepatogastroenterology. 2007; 54: 1074-1079.

상세보기
Jarnerot G, Hertervig E, Friis-Liby I, et al., Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-1811.

상세보기
Rutgeerts P, Sandborn WJ , Feagan BG, et al., Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476.

상세보기
Armuzzi A, De Pascalis B, Lupascu A. et al., Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci. 2004; 8: 231-233.
Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol. 2004; 16: 1167-1171.

상세보기
Probert CJ, Hearing SD, Schreiber S, et al., Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003; 52: 998-1002.

상세보기
Sands BE, Tremaine WJ, Sandborn WJ, et al., Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Infl amm Bowel Dis. 2001; 7: 83-88.

상세보기
Irvine EJ. A quality-of-life index for inflammatory bowel disease. Can J Gastroenterol. 1993; 7: 155-159.

상세보기
Egger M, Davey SG. Meta-analysis: potentials and premise. BMJ. 1997; 315: 1371-1374.

상세보기
Choi YY, Sohn HY, Shin HT. Clinical Benefits of Selfmonitoring of blood glucose in non-insulin treated patients with type 2 diabetes: a systematic review and metaanalysis. Kor J Clin Pharm. 2010; 20: 183-192.
Ford AC, Sandborn WJ, Khan KJ, et al., Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644-659.

상세보기
Huang X, Lv B, Jin HF, et al., A meta-analysis of the therapeutic effects of tumor necrosis factor- ${\alpha}$ blockers on ulcerative colitis. Eur J Clin Pharmacol. 2011;67:759-766

상세보기
Samsa G, Edelman D, Rothman ML, et al., Determining clinically important differences in health status measures: a general approach with illustration to the health utilities index mark II. Pharmacoeconomics. 1999; 15: 141-155.

상세보기
Hjortswang H, Jarnerot G, Curman B, et al., The Short Health Scale: a valid measure of subjective health in ulcerative colitis. Scand J Gastroenterol. 2006; 41: 1196-1203.

상세보기
Sullivan M, Karlsson J, Ware JE Jr. The Swedish SF-36 Health Survey - I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med. 1995; 41: 1349-1358.

상세보기
Taft C, Karlsson J, Sullivan M. Performance of the Swedish SF-36 version 2.0. Qual Life Res. 2004; 13: 251-256

상세보기
Irvine EJ, Feagan B, Rochon J, et al., Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994; 106: 287-296.

상세보기
Walmsley RS, Ayres RC, Pounder RE, et al., A simple clinical colitis activity index. Gut. 1998; 43: 29-32.

상세보기
Seo M, Okada M, Maeda K, et al., Correlation between endoscopic severity and the clinical activity in ulcerative colitis. Am J Gastroenterol. 1998; 93: 2124-2129.

상세보기
Higgins PD, Schwarts M, Mapili J, et al., Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol. 2005; 100: 355-361.

상세보기
Williams A. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990; 16: 199-208.

상세보기
Gurwitz JH, Bohn RL, Glynn RJ, et al., Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994; 154:97-101.

상세보기
Clowes JA, Peel N, Eastell R. Glucocorticoid-induced osteoporosis. Curr Opin Rheumatol. 2001; 13:326-332.

상세보기

저자의 다른 논문 :

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증